KESORAT

This brand name is authorized in Nigeria.

Active ingredients

The drug KESORAT contains one active pharmaceutical ingredient (API):

1	Loratadine UNII 7AJO3BO7QN - LORATADINE
	Loratadine is a tricyclic antihistamine with selective, peripheral H1-receptor activity. Loratadine has no clinically significant sedative or anticholinergic properties in the majority of the population and when used at the recommended dosage.
	Read more about Loratadine

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
B4-9573	Tablet	KESORAT TABLETS TAB 10 mg 10 X 10	70 RNW-PP-394485 KESORAT TABLETS LORATADINE 10MG Loratadine USP 10mg. Excipients: Lactose BP, Microcrystalline Cellulose BP, Maize starch BP, P.V.P.K 30 (Povidone) BP, Sodium methyl Paraben BP, Sodium propyl Paraben BP, Purified Water BP, Sodium starch glycolate BP, Colloidal silicon Dioxide BP, Purified Talc BP, Magnesium Stearate BP, Aspartame BP B4-9573 Drugs Imported Products 10X10 OTC 12/6/2023 KESSINGTON GLOBAL SYNERGY LTD, GOVERNORS WAY MAPLE WOOD ESTATE OKO-OBA LAGOS AGEGE LAGOS 9093313563 sammville@gmail.com RATNATRIS PHARMACEUTICALS PVT.,LTD, SURVEY N0.416, AT.INDRAD, TA. KADI. DIST MEHSANA-382715, GUJARAT, INDIA, India	28/02/2024

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R06AX13	Loratadine	R Respiratory system → R06 Antihistamines for systemic use → R06A Antihistamines for systemic use → R06AX Other antihistamines for systemic use
Discover more medicines within R06AX13

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	B4-9573